

# Bryan, Garnier & Co. Healthcare Conference



Paris, 15 November 2016

This presentation contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements contained in this presentation.

# A Global Leader In HealthCare Products And Services

















### A Global Leader In HealthCare Products And Services




#### ~€27.6 bn in Sales

(as of Dec. 31, 2015)

Strong portfolio of products (30% of sales) and services (70% of sales) Total Shareholder Return: 10-year CAGR: ~20% Global presence in 100+ countries

222,000+ employees worldwide (as of Dec 31, 2015)


# Total Shareholder Return – CAGR, rounded




Source: Bloomberg; dividends reinvested

# Fresenius Group: Consistent Cash Generation And Proven Track Record of Deleveraging


### CFFO margin




#### FCF margin (before acquisitions & dividends)



#### Capex in % of sales



#### Net Debt / EBITDA<sup>1</sup>



<sup>1</sup> 2011 – 2015 adjusted due to debt issuance cost restatement (U.S. GAAP standard ASU 2015-03)

# Strong, Diversified Product And Service Portfolio











Ownership: 31%



Ownership: 100%



Ownership: 100%



Ownership: 77%

Dialysis Products	Hospital Supplies	Hospital Operations	Hospital Projects
Healthcare Services	and Services		and Services
Sales 2015: US\$16.7 bn	Sales 2015: €6.0 bn	Sales 2015: €5.6 bn	Sales 2015: €1.1 bn

# Fresenius Medical Care: Global Dialysis Market Leader

- The world's leading provider of dialysis products and services treating 306,366 patients in 3,579 clinics<sup>1</sup>
- Provide highest standard of product quality and patient care

ရှိခဲ့ Dialysis products

Dialysis services



• Expansion in Care Coordination and global dialysis service opportunities; enter new geographies

**Market Dynamics** 

#### **Global Dialysis Market 2015:**

- ~US\$73 bn
- ~6% patient growth p.a.

#### **Growth Drivers:**


 Aging population, increasing incidence of diabetes and high blood pressure, treatment quality improvements



<sup>1</sup> As of Sep 30, 2016

# Fresenius Kabi: A Leading Global Hospital Supplier

- Comprehensive product portfolio for critically and chronically ill patients
- Strong Emerging Markets presence
- Leading market positions in four product segments



 Focus on organic growth through geographic product rollouts and new product launches


#### **Market Dynamics**

#### Global Addressable Market 2015:

• >€33 bn

#### **Growth Drivers:**

 Patent expirations, rising demand for health care services, higher health care spending in Emerging Markets



# **Fresenius Helios: Leading German Hospital Operator**

- ~6% share in German acute care hospital market
- Strong track record in hospital acquisitions and operations
- High-quality medical care, e.g., mortality rate for heart failure and pneumonia below German average
- Comprehensive healthcare services coverage





Outpatient

<sup>1</sup> German Federal Statistical Office 2015; total costs, gross of the German hospitals less academic research and teaching

#### **Market Dynamics**

#### German Acute Care Hospital Market:

• ~€91 bn<sup>1</sup>

#### **Growth Drivers:**

• Aging population leading to increasing hospital admissions, further market consolidation

#### Majority of population has access to a HELIOS hospital within one hour's drive<sup>2</sup>



- 112 hospitals
- >34,000 beds
- ~1.3 million inpatient admissions
- ~3.4 million outpatient admissions

<sup>2</sup> As of Sep 30, 2016

# Fresenius Vamed: Leading Global hospital Projects And Services Specialist

 Manages hospital construction/expansion projects (51% of sales) and provides services (49% of sales) for health care facilities worldwide





#### **Market Dynamics**

#### **Growth Drivers:**

- Emerging Market demand for building and developing hospital infrastructure
- Outsourcing of non-medical services from public to private operators
- Offers project development, planning, turnkey construction, maintenance as well as technical management, and total operational management
  - Strong track record: More than 760 projects in 78 countries completed



# Fresenius Group: 2016 Financial Outlook by Business Segment

			Old	New
5	FRESENIUS KABI	Sales growth organic	3% – 5%	4% – 6%
		EBIT growth (cc)	3% – 5%	4% - 6%
	FRESENIUS HELIOS	Sales growth organic	3% – 5%	unchanged
		EBIT	€670 – 700 m	unchanged
V	FRESENIUS VAMED	Sales growth organic	5% – 10%	unchanged 🖌
		EBIT growth	5% – 10%	unchanged 🗹

# Fresenius Group: 2016 Financial Guidance

		2015	2016		
		Actual	Old	New	
<b>F</b> FRESENIUS	Sales growth constant currency	€27.6 bn	6% – 8%	unchanged	
	Net income <sup>1</sup> growth constant currency	€1,423 m	11% – 14%	12% – 14%	

<sup>1</sup> Net income attributable to shareholders of Fresenius SE & Co. KGaA; 2015 before special items



# Financials Q3/16

















# Fresenius Group: Q3/2016 Highlights




# Acquisition of Quirónsalud: Transaction Highlights



Combination forms powerful platform for **knowledge & best practice transfer** 

Substantial cost and growth synergies






**New mid-term targets** for **Fresenius Group** as part of its FY 2016 reporting








# Acquisition of Quirónsalud: Broad Revenue Base




HIC = Health Insurance Companies; NHS = National Health Care System


# Acquisition of Quirónsalud: Financial Outlook



# Acquisition of Quirónsalud: Integration by Interaction



# Fresenius Group: Q3/2016 Key Financials



Constant currency growth rates 2015 EBIT before special items Net income attributable to shareholders of Fresenius SE & Co. KGaA; 2015 before special items

# **Fresenius Group: Profit and Loss Statement**

€m	Q3/2016	Δ Q3 YoY <sup>1</sup>	Q1-3/2016	Δ Q1–3 YoY <sup>1</sup>
Sales	7,339	7%	21,345	6%
EBIT <sup>2</sup>	1,082	6%	3,092	9%
Net interest	-142	2%	-433	8%
Income taxes <sup>2</sup>	-255	2%	-746	-7%
Net income <sup>2,3</sup>	399	10%	1,154	15%


<sup>1</sup> Constant currency growth rates

<sup>2</sup> 2015 before special items

<sup>3</sup> Net income attributable to shareholders of Fresenius SE & Co. KGaA

For a detailed overview of special items please see the reconciliation tables on slides 27–28.

# Fresenius Group: Q3/2016 Key Financials



2015 EBIT before special items

		Q3/2016	ΔQ3 YoY
FRESENIUS	Sales	US\$4,598 m	9%
MEDICAL CARE	EBIT	US\$670 m	9%
	Sales	€1,511 m	1%
	EBIT <sup>1</sup>	€300 m	0%
FRESENIUS	Sales	€1,470 m	6%
HELIOS	EBIT <sup>1</sup>	€175 m	6%
FRESENIUS	Sales	€268 m	0%
VAMED	EBIT	€15 m	7%

<sup>1</sup> 2015 before special items

For a detailed overview of special items please see the reconciliation tables on slides 27-28.

### **FRESENIUS**

# Fresenius Kabi (1/2): Key Topics Q3/2016

### North America

- 2% organic sales growth in Q3/16 despite tough PY quarter
- Gradual easing of IV drug shortages: 16 Kabimarketed products currently designated in shortage vs. 17 at the end of Q2/16
- 6 product launches YTD; confirm top end of 6 to 10 target range for FY/16

Product Name	Product Group	Launch Date
Amikacin	Anti-infective	Q1
Linezolid	Anti-infective	Q2
Chloramphenicol	Anti-infective	Q2
SmofLipid	Lipid emulsion	Q3
Daptomycin	Anti-infective	Q3
<b>Ketorolac</b> (pre-filled syringe)	Analgesic	Q3

• Increase outlook: Low to mid single-digit organic sales growth for FY/16 (Previous: Low single-digit)

#### Europe

- 3% organic sales growth in Q3/16
- On track to meet outlook of low to mid single-digit organic sales growth for FY/16



# Fresenius Kabi (2/2): Key Topics Q3/2016

### **Emerging Markets**

#### China

- 9% organic sales growth in Q3/16
- New tender rules:
  - 10 out of 31 provinces have finalized tender process
  - Expect low single-digit price impact in FY16
- Sustainable double-digit volume growth
  expected

#### Asia-Pacific ex China

• 10% organic sales growth in Q3/16


#### Latin America/Africa

• 7% organic sales growth in Q3/16

#### **Emerging Markets overall**

• **On track** to meet FY/16 outlook of likely low double-digit organic sales growth

China tender situation: Applicable to Kabi's Pharmaceutical and Nutrition business



Disclaimer: This update is only intended to give a general picture of the drug purchase tendering status of each province / direct-controlled city in China. The status may vary between type of drugs, specific products or specific area /hospital.

# Fresenius Kabi: Organic Sales Growth by Regions

€m	Q3/2016	Organic Growth	Q1–3/2016	Organic Growth
Europe	521	3%	1,569	2%
North America	542	2%	1,628	5%
Asia-Pacific	290	9%	821	8%
Latin America/Africa	158	7%	439	16%
Total sales	1,511	5%	4,457	6%

# Fresenius Kabi: Organic Sales Growth by Product Segment

€m	Q3/2016	Organic Growth	Q1–3/2016	Organic Growth
IV Drugs	620	2%	1,871	5%
Infusion Therapy	217	3%	636	5%
Clinical Nutrition	403	7%	1,173	7%
Medical Devices/ Transfusion Technology	271	7%	777	5%
Total sales	1,511	5%	4,457	6%

# Fresenius Kabi: EBIT

€m	Q3/2016	ΔQ3 YoY <sup>1</sup>	Q1-3/2016	$\Delta$ Q1–3 YoY <sup>1</sup>
Europe	80	-2%	243	-3%
Margin	15.4%	-70 bps	15.5%	-90 bps
North America	216	7%	669	11%
Margin	39.9%	170 bps	41.1%	220 bps
Asia-Pacific/Latin America/Africa	<b>94</b>	11%	245	18%
Margin	21.0%	80 bps	19.4%	220 bps
Corporate and Corporate R&D	-90	-26%	-241	-20%
<b>Total EBIT</b>	<b>300</b>	<b>1%</b>	<b>916</b>	<b>7%</b>
Margin	19.9%	-20 bps	20.6%	90 bps

<sup>1</sup> Constant currency growth rates

2015 before special items Margin growth at actual rates

For a detailed overview of special items please see the reconciliation tables on slides 27-28.

### **FRESENIUS**


# Fresenius Helios: Key Topics Q3/2016

### Germany

- **4% organic sales growth** in Q3/16 driven by admissions increase
- Ongoing favorable reimbursement environment: 2017 DRG inflator set at 2.50%

### Quirónsalud

- Closing process and debt financing
  progressing
- On track to meet FY/16 outlook:
  - Sales of €2.5 bn
  - EBITDA of €460 to 480 m





<sup>1</sup> Organic sales growth

# **Fresenius Helios: Strong Sales Growth**

€m	Q3/2016	Δ Q3 ΥοΥ	Q1-3/2016	Δ Q1–3 YoY
Established clinic portfolio	1,454	4%	4,352	4%
Acquisitions (consolidation <1 yr)	16	n.a.	30	n.a.
Total Sales	1,470	6%	4,382	5%

2015 before special items

For a detailed overview of special items please see the reconciliation tables on slides 27–28.

€m	Q3/2016	ΔQ3 YoY	Q1-3/2016	Δ Q1-3 YoY
Total sales	1,470	6%	4,382	5%
<b>EBIT</b> Established clinic portfolio	174	5%	506	7%
Margin	12.0%	20 bps	11.6%	30 bps
Acquisitions / Divestitures (consolidation / deconsolidation <1 yr) Margin	1 6.3%		1 3.3%	
<b>Total EBIT</b> Margin	<b>175</b> 11.9%	<b>6%</b> 10 bps	<b>507</b> 11.6%	<b>7%</b> 30 bps

2015 before special items

For a detailed overview of special items please see the reconciliation tables on slides 27–28.

### **FRESENIUS**

# Fresenius Helios: 2015 Clinic Development Plan

	Years in Portfolio								
	<1	1	2	3	4	5 <sup>1</sup>	6	>6	Total <sup>1</sup>
No. of clinics	1	-	-	12	3	40	-	55	111
Revenue (€m)	7	-	-	410	173	2,002	-	2,837	5,429
Target									
EBIT margin (%)	-	2.0	4.0	6.0	8.0	10.0	12.0	12.0 – 15.0	
EBIT (€m)	-	-	-	24.6	13.8	200.2	-	340.5	579.1
Reported									
EBIT margin (%)	6.2	-	-	9.8	6.9	10.4	-	13.2	11.7
EBIT (€m)	0.4	-	-	40.1	11.9	207.9	-	373.3	633.6
No. of clinics > target	_	_	_	8	1	19	-	25	53
No. of clinics < target	-	-	-	4	2	21	-	30	57

<sup>1</sup> Includes all hospitals acquired from Rhön Klinikum, €12 m integration costs allocated to individual hospitals.

### **Fresenius Helios: Performance Indicators**

	Q1-3/2016	Q1-3/2015	Change
No. of hospitals <sup>1</sup>	112	111	1%
- Acute care clinics	88	87	1%
- Post-acute care clinics	24	24	0%
No. of beds <sup>1</sup>	34,701	34,076	2%
- Acute care clinics	29,613	28,914	2%
- Post-acute care clinics	5,088	5,162	-1%
Admissions			
- Acute care (inpatient)	923,134	891,654	4%
Occupancy			
- Post-acute care	83%	83%	
Average length of stay (days)			
- Acute care <sup>2</sup>	6.4	6.5	
- Post-acute care	26.1	26.5	

<sup>1</sup> December 31, 2015

<sup>2</sup> German average (2015): 7.3

- 1% organic sales growth in Q3/16 reflects typical quarterly fluctuations of project business
- Continued strong order intake with good regional diversification



€m	Q3/ 2016	Δ	Q1-3/ 2016	Δ
Project business	130	-1%	325	-2%
Service business	138	1%	415	4%
Total sales	268	0%	740	1%
Total sales Total EBIT	268 15	0% 7%	740 31	1% 3%

<sup>1</sup> Project business only

<sup>2</sup> Versus December 31, 2015

# Fresenius Group: Overview – Calculation of Noncontrolling Interest

€m	Q1-3/2016	FY/2015
Earnings before tax and noncontrolling interest	2,659	3,262
Taxes	-746	-965
Noncontrolling interest, thereof	-759	-939
Fresenius Medical Care net income not attributable to Fresenius (Q1-3/16: ~69%)	-530	-641
Noncontrolling interest holders in Fresenius Medical Care (Q1–3/16: US\$217 m according to Fresenius Medical Care's Financial Statements)	-195	-256
Noncontrolling interest holders in Fresenius Kabi (-€27 m), Fresenius Helios (-€1 m), Fresenius Vamed (-€1 m) and due to Fresenius Vamed's 23% external ownership (-€5 m)	-34	-42
Net income attributable to Fresenius SE & Co. KGaA	1,154	1,358

# **Fresenius Group: Cash Flow**

	Operat	ing CF	Capex	(net)	Free Cas	sh Flow <sup>1</sup>
€m	Q3/2016	LTM Margin	Q3/2016	LTM Margin	Q3/2016	LTM Margin
FRESENIUS KABI	311	16.2%	-83	-5.4%	228	10.8%
FRESENIUS HELIOS	207	11.5%	-74	-5.3%	133	6.2% <sup>3</sup>
	21	10.6%	-2	-0.8%	19	9.8%
Corporate/Other	-3	n.a.	-2	n.a.	-5	n.a.
FRESENIUS Excl. FMC	536	14.4% <sup>2</sup>	-161	-5.1%	375	<b>9</b> .3% <sup>2</sup>
	929	12.0%	-372	-5.5%	557	6.5%

<sup>1</sup> Before acquisitions and dividends

<sup>2</sup> Margin incl. FMC dividend

<sup>3</sup> Understated: 7.1% excluding €51 million of capex commitments from acquisitions

### **FRESENIUS**


	Operat	ing CF	Capex	(net)	Free Cas	h Flow <sup>1</sup>
€m	Q1-3/2016	LTM Margin	Q1-3/2016	LTM Margin	Q1-3/2016	LTM Margin
	646	16.2%	-208	-5.4%	438	10.8%
FRESENIUS HELIOS	437	11.5%	-176	-5.3%	261	6.2% <sup>3</sup>
	22	10.6%	-6	-0.8%	16	9.8%
Corporate/Other	-7	n.a.	-5	n.a.	-12	n.a.
FRESENIUS Excl. FMC	1,098	14.4% <sup>2</sup>	-395	-5.1%	703	<b>9</b> .3% <sup>2</sup>
FRESENIUS	2,259	12.0%	-1.052	-5.5%	1,207	6.5%

<sup>1</sup> Before acquisitions and dividends <sup>2</sup> Margin incl. FMC dividend

<sup>3</sup> Understated: 7.1% excluding €51 million of capex commitments from acquisitions

€m	Q3/2016	LTM Margin	Q3/2015 L	TM Margin	Δ ΥοΥ
Operating Cash Flow	929	12.0%	900	11.3%	3.2%
Capex (net)	-372	-5.5%	-327	-5.2%	-13.8%
Free Cash Flow (before acquisitions and dividends)	557	6.5%	573	6.1%	-2.8%
Acquisitions (net)	-40		-47		
Dividends	-58		-59		
Free Cash Flow (after acquisitions and dividends)	459	3.1%	-467	1.4%	-1.7%

### **Fresenius Group: Leverage Ratio**



<sup>1</sup> Pro forma acquisitions; before special items

<sup>2</sup> Adjusted due to debt issuance cost restatement (U.S. GAAP standard ASU 2015-03)

<sup>3</sup> Pro forma excluding advances made for the acquisition of hospitals from Rhön-Klinikum AG; before special items

<sup>4</sup> Before special items

<sup>5</sup> 2015 before special items

At annual average FX rates for both EBITDA and net debt

# Reconciliation according to U.S. GAAP Q3 2016/Q3 2015

The Group's U.S. GAAP financial results as of September 30, 2016 do not include special items, whereas the U.S. GAAP financial results as of September 30, 2015 include special items. Net income attributable to shareholders of Fresenius SE & Co. KGaA was adjusted for these special items. The table below shows the special items and the reconciliation from net income (before special items) to earnings according to U.S. GAAP.

Net income attributable to shareholders of Fresenius SE & Co. KGaA	367	-6	-4	0	357
Noncontrolling interest	-252				-252
Net income	619	-6	-4	0	609
Income taxes	-262	4			-258
Net income before taxes	881	-10	-4	0	867
Interest result	-146				-146
EBIT	1,027	-10	-4	0	1,013
Sales	6,940				6,940
€m	Q3/2015 before special items	efficiency program KABI	integration costs for acquired Rhön hospitals	disposal gains from two HELIOS hospitals	according to U.S. GAAP (incl. special items)

The special items are reported in the Group Corporate/Other segment.

03/2015

The Group's U.S. GAAP financial results as of September 30, 2016 do not include special items, whereas the U.S. GAAP financial results as of September 30, 2015 include special items. Net income attributable to shareholders of Fresenius SE & Co. KGaA was adjusted for these special items. The table below shows the special items and the reconciliation from net income (before special items) to earnings according to U.S. GAAP.

Net income attributable to shareholders of Fresenius SE & Co. KGaA	1,009	-34	-10	34	999
Noncontrolling interest	-661				-661
Net income	1,670	-34	-10	34	1,660
Income taxes	-703	16	2		-685
Net income before taxes	2,373	-50	-12	34	2,345
Interest result	-476				-476
EBIT	2,849	-50	-12	34	2,821
Sales	20,369				20,369
€m	Q1–3/2015 before special items	efficiency program KABI	integration costs for acquired Rhön hospitals	disposal gains from two HELIOS hospitals	according to U.S. GAAP (incl. special items)

The special items are reported in the Group Corporate/Other segment.

01 2/201E

# **Share Information**

Share key facts	
Number of shares <sup>1</sup>	546,932,731
WKN / ISIN	578560 / DE0005785604
Ticker symbol	FRE
Bloomberg symbol	FRE GR
Reuters symbol	FREG.de
ADR key facts	
<b>ADR key facts</b> Ratio	4 ADRs = 1 ordinary share
	4 ADRs = 1 ordinary share 35804M105 / US35804M1053
Ratio	5
Ratio ADR CUSIP / ISIN	35804M105 / US35804M1053
Ratio ADR CUSIP / ISIN Ticker symbol	35804M105 / US35804M1053 FSNUY

<sup>1</sup> As of September 30, 2016

# Financial Calendar / Contact

#### Financial Calendar 2017

22.02.2017	Report on Fiscal Year 2016
03.05.2017	Report on 1 <sup>st</sup> quarter 2017
12.05.2017	Annual General Meeting, Frankfurt/Main
01.08.2017	Report on 2 <sup>nd</sup> quarter 2017
02.11.2017	Report on 3 <sup>rd</sup> quarter 2017

Please note that these dates could be subject to change.

### Contact

Investor Relations

Fresenius SE & Co. KGaA

phone: +49 6172 608-2485

e-mail: ir-fre@fresenius.com

For further information and current news: www.fresenius.com

Follow us on Twitter	www.twitter.com/fresenius_ir
and LinkedIn:	www.linkedin.com/company/fresenius-investor-relations

#### **FRESENIUS**